Allergy Immunotherapy Market Analysis

Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis)

The rhinitis segment is expected to hold a significant share of the allergy immunotherapy market during the forecast period. According to a survey, rhinitis and asthma impact 23 million people in the US each year. In the same region, an additional 50 million people suffer from another type of allergy. One of the major drivers of the market expansion is the increased investment made by major manufacturers in the development of AIT medications to treat different allergies. Therefore, it is anticipated that allergic rhinitis will fuel the segment's expansion.

Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy)

The subcutaneous immunotherapy segment would account for more than 53% of the allergy immunotherapy market. Subcutaneous immunotherapy (SCIT) is a cutting-edge method for treating allergic diseases because it alters allergic diseases by concentrating on the underlying immunological mechanism. Numerous carefully monitored clinical trials have demonstrated its efficacy and safety in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and hypersensitivity to stinging insects. Subcutaneous immunotherapy (SCIT), which is administered via injection, is frequently referred to as an "allergy shot". It provides symptomatic relief for those with asthma and allergic rhinitis and is the standard treatment for allergen desensitization. Increased prevalence of allergic disorders and high demand for improved procedures are some of the factors driving the growth of the segment. According to estimates, between 11 and 26 million people in Europe have food allergies. With a population of 7 billion people, this rate amounts to 240–550 million people who could be food allergies, which is a significant global health burden.

Our in-depth analysis of the global market includes the following segments: